卡博替尼治疗肝细胞癌:一项2期安慰剂对照随机停药研究的结果
这项2期随机停药试验在41例Child-Pugh A级、≤1线既往系统治疗的肝细胞癌患者中评估卡博替尼(起始100 mg/日)。12周时客观缓解率为5%,疾病控制率66%,≥1次基线后扫描者中78%肿瘤缩小;12周稳定疾病者随机后卡博替尼组与安慰剂组中位无进展生存期分别为2.5个月和1.4个月,差异无统计学意义。
要点
- 12周客观缓解率5%,2例确认部分缓解,疾病控制率66%(亚裔亚组73%)。
- 随机后中位无进展生存期卡博替尼2.5个月 vs 安慰剂1.4个月,无统计学显著差异。
- 最常见3/4级不良事件为腹泻20%、手足综合征15%、血小板减少15%,59%患者减量。
核心结论
- 卡博替尼在肝细胞癌患者中具有临床活性,包括客观肿瘤缓解、疾病稳定和甲胎蛋白下降,不良事件通过减量管理。
研究设计与样本
- 2期安慰剂对照随机停药试验,纳入9个肿瘤类型队列,肝细胞癌为其中之一。
- 入组患者肝功能为Child-Pugh A级,既往系统抗肿瘤方案≤1种且完成≥4周。
- 卡博替尼起始剂量100 mg每日一次,先经12周治疗,稳定疾病者随机至卡博替尼或安慰剂。
- 导入阶段主要终点为第12周客观缓解率,随机阶段主要终点为无进展生存期。
- 共入组41例肝细胞癌患者,其中22例第12周稳定疾病者被随机。
主要发现
- 第12周客观缓解率为5%,2例患者达到确认的部分缓解。
- 第12周疾病控制率(部分缓解或稳定疾病)为66%,亚裔亚组为73%。
- 有≥1次基线后扫描的患者中78%出现肿瘤缩小,与既往索拉非尼治疗无明显关系。
- 基线甲胎蛋白升高且有≥1次基线后检测的26例中,9例(35%)出现甲胎蛋白应答(较基线下降>50%)。
- 随机后中位无进展生存期卡博替尼组2.5个月 vs 安慰剂组1.4个月,差异无统计学意义;全部患者自第1天起中位无进展生存期5.2个月、总生存期11.5个月。
关键数值与推荐
- 第12周客观缓解率5%,确认部分缓解2例;疾病控制率66%(亚裔亚组73%)。
- 有≥1次基线后扫描者中78%肿瘤缩小;基线甲胎蛋白升高者中9/26(35%)出现甲胎蛋白应答。
- 随机后中位无进展生存期卡博替尼2.5个月 vs 安慰剂1.4个月,差异无统计学意义。
- 全部患者自第1天起中位无进展生存期5.2个月、总生存期11.5个月。
- 最常见3/4级不良事件(不论归因)为腹泻20%、手足综合征15%、血小板减少15%;59%患者使用减量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and VEGF receptors, was assessed in patients with hepatocellular carcinoma (HCC) as part of a phase 2 randomized discontinuation trial with nine tumor-type cohorts. PATIENTS AND METHODS: Eligible patients had Child-Pugh A liver function and ≤1 prior systemic anticancer regimen, completed ≥4 weeks before study entry. The cabozantinib starting dose was 100 mg daily. After an initial 12-week cabozantinib treatment period, patients with stable disease (SD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 were randomized to cabozantinib or placebo. The primary endpoint of the lead-in stage was objective response rate (ORR) at week 12, and the primary endpoint of the randomized stage was progression-free survival (PFS). RESULTS: Among the 41 HCC patients enrolled, the week 12 ORR was 5%, with 2 patients achieving a confirmed partial response (PR). The week 12 disease control rate (PR or SD) was 66% (Asian subgroup: 73%). Of patients with ≥1 post-baseline scan, 78% had tumor regression, with no apparent relationship to prior sorafenib therapy. Alpha-fetoprotein (AFP) response (>50% reduction from baseline) occurred in 9 of the 26 (35%) patients with elevated baseline AFP and ≥1 post-baseline measurement. Twenty-two patients with SD at week 12 were randomized. Median PFS after randomization was 2.5 months with cabozantinib and 1.4 months with placebo, although this difference was not statistically significant. Median PFS and overall survival from Day 1 in all patients were 5.2 and 11.5 months, respectively. The most common grade 3/4 adverse events, regardless of attribution, were diarrhea (20%), hand-foot syndrome (15%), and thrombocytopenia (15%). Dose reductions were utilized in 59% of patients. CONCLUSIONS: Cabozantinib has clinical activity in HCC patients, including objective tumor responses, disease stabilization, and reductions in AFP. Adverse events were managed with dose reductions. TRIAL REGISTRATION NUMBER: NCT00940225.
引用
- Kelley RK, Verslype C, Cohn AL, et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol. 2017. PMID: 28426123. doi:10.1093/annonc/mdw651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。